Cowpox to COVID: History of vaccination in the immunocompromised host

Abstract

AbstractBackgroundThe use of vaccination to prevent infection has a long history, starting in the 1700s with Jenner. New innovations have led to improvements in the safety and efficacy of vaccines, from live attenuated viruses to subunit vaccines, to RNA‐based vaccination for SARS‐CoV‐2. Despite this progress, however, solid organ transplant (SOT) recipients on immunosuppression demonstrate an impaired vaccine response compared with healthy controls. This issue is important given the increased vulnerability to infection in immunocompromised patients, especially in the setting of the Coronavirus Disease 2019 (COVID‐19) pandemic.MethodsWe reviewed the literature on key topics in vaccination with significant clinical impact on SOT patients.ResultsPrior to COVID‐19, a large amount of data has been published demonstrating impaired humoral and T‐cell responses to multiple vaccinations targeting influenza, hepatitis B, VZV, and Pneumococcus. Poor immunogenicity can be addressed through the use of adjuvants to boost the immune response, even in the setting of senescence related to age or immunosuppression. New vaccines provide hope for preventing infection due to hepatitis C and Cytomegalovirus, and to the emerging infection, monkeypox. The data on the impact of the COVID‐19 vaccine in SOT patients is reviewed, with a focus on seroconversion, antibody titer, and antigen‐specific T cells. Factors associated with impaired response, including mycophenolate, are described.ConclusionThe history of vaccination demonstrates how scientific breakthroughs can be applied to clinical challenges. New approaches using adjuvants, strategic antigen selection, and RNA‐based vaccines offer the potential to improve immune response in SOT recipients. Future innovations are needed to better protect the vulnerable immunocompromised host.